AstraZeneca stock heads into the open after a 0.58 percent gain
Published on 09/21/2026 at 06:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock closed at 12,500.0 pence on the London Stock Exchange on September 18, 2026, gaining 0.58 percent on the day. Compared with the noted 52-week high of GBP 157.32, the latest close leaves the shares some distance below that peak while still trading near recent highs.
September 18, 2026 in numbers
AstraZeneca PLC (ISIN GB0009895292) finished the September 18, 2026 session in London at 12,500.0 pence, up 72.0 pence or 0.58 percent versus the prior close, according to data cited from Investing.com in reports on Ad-hoc-news. The stock traded within a day range between 12,398.0 and 12,596.0 pence, with a reported volume of 6.52 million shares on its primary London Stock Exchange listing, providing solid liquidity into the weekend. On the same day, the broader FTSE 100 benchmark was reported to move modestly higher in global market wrap coverage, so AstraZeneca's gain slightly outpaced the typical large-cap reference environment.
As Ad-hoc-news reported on September 20, 2026, the advance was driven in part by Deutsche Bank upgrading its stance on AstraZeneca and nudging its price target to 11,700 pence after a pivotal lung cancer study update. The same report highlighted that analysts now see potential upside for the shares toward around GBP 150.00, underscoring how the combination of the bank's rating change and the positive oncology trial commentary supported sentiment in the last session. A related corporate-news summary from Ad-hoc-news also noted that insider share purchases by AstraZeneca's chief executive added to the positive tone, with the shares trading near recent highs as investors digested the upgraded view and clinical data backdrop.
Today’s drivers for AstraZeneca
Into today's session on September 21, 2026, market attention around AstraZeneca remains shaped by the recent Deutsche Bank upgrade and the lung cancer trial update, with the bank's revised 11,700 pence price target and commentary continuing to frame expectations for the stock, as detailed by Sharecast. The broker recommendations overview there confirms that Deutsche Bank shifted AstraZeneca from a sell rating to hold, citing a changed risk-reward profile after last week's negative SERENA-4 readout and a period of underperformance against European large-cap peers, which may influence how investors position ahead of the opening bell today. In addition, global market briefings such as the recent daily summary on TradingKey indicate that major United States indices, including the S&P 500 and Nasdaq Composite, ended their latest session slightly higher, suggesting a generally constructive backdrop for risk assets that could also color sentiment toward large pharmaceutical names like AstraZeneca as the London market prepares to reopen.
